| Description | HB007 is a potent degrader of small ubiquitin-related modifier 1 (SUMO1). It mediates the ubiquitination and subsequent degradation of SUMO1, leading to a decrease in tumor growth in vivo. HB007 is a valuable tool for investigating brain, breast, colon, and lung cancers[1][2]. |
| In vitro | HB007 (compound 24) (0.1-100 μM) inhibits LN229 cell growth in a concentration-dependent manner t[1].HB007 (10-25 μM) reduces SUM01 conjugation and total protein levels of SUM01 but not SUM02/3 or UB in LN229 cells t[1]. |
| In vivo | HB007 (compound 24) (25-50 mg/kg; i.p. for 15 d) significantly suppresses tumor growth of colon and lung cancer but had no effect on the body weights of mice[1]. |
| molecular weight | 328.78 |
| Molecular formula | C15H9ClN4OS |
| CAS | 2387821-46-5 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Bellail AC, et, al. Ubiquitination and degradation of SUMO1 by small-molecule degraders extends survival of mice with patient-derived tumors. Sci Transl Med. 2021 Oct 13;13(615):eabh1486. 2. BELLAIL A, et, al. Compositions and methods for treating cancer. WO2019217509A1. |